What IBM Watson's Failure Tells Us About Every AI Hype Cycle That Follows

On February 16, 2011, a computer system built by IBM defeated Ken Jennings and Brad Rutter on Jeopardy! and won $1 million. Ken Jennings, who had won 74 consecutive games of Jeopardy! — a record that will probably never be broken — wrote on his final answer card: “I, for one, welcome our new computer overlords.”

It was funny. It was generous. And it started an avalanche of corporate decision-making that would cost IBM and its clients somewhere north of a billion dollars in destroyed value, failed projects, and reputational damage that the company has still not fully recovered from fifteen years later.

Watson failed. Spectacularly, specifically, and in ways that were almost entirely predictable from first principles. Understanding how requires going back to what Watson actually was, which turns out to be very different from what IBM told the world it was.

Watson was an information retrieval and natural language processing system. It was genuinely impressive at what it did: parsing questions in natural language, searching a curated knowledge base, and returning ranked answers with confidence scores. For Jeopardy!, which is essentially a very specific information retrieval game with a theatrical format, it worked beautifully. The question-answering domain was constrained. The knowledge base was curated by IBM engineers over years. The success metrics were clear and the evaluation process was rigorous. IBM’s team, led by David Ferrucci, did extraordinary engineering work to make it function under those conditions.

IBM’s sales team took that performance and sold something categorically different: a cognitive computing system that could reason through complex domains the way a human expert would, autonomously and at scale. They sold this to MD Anderson Cancer Center in Houston, which signed on in 2013 to deploy Watson for oncology decisions. They sold it to Memorial Sloan Kettering. To Cleveland Clinic. To dozens of financial institutions, insurance companies, and law firms. IBM had a stated goal of making Watson a $10 billion revenue business within a few years of the Jeopardy! win.

The MD Anderson project cost $62 million before the University of Texas audit found that Watson had recommended “unsafe and incorrect” cancer treatments and the project was shut down in 2017. Not paused. Shut down. The system had been trained largely on synthetic patient data rather than actual case histories, which meant its recommendations were calibrated to fictional patients in ways that diverged from real clinical patterns in dangerous ways. The whole architecture was wrong for the application, and nobody with the authority to stop it caught this early enough, because the people selling Watson and the people buying it shared a common misconception about what the system was doing. Both sides were working from the same wrong mental model.

The misconception was this: IBM sold Watson as if it were autonomous. As if the system could be given a medical domain and would figure it out from available literature, the way a brilliant resident would read journals, integrate evidence from diverse sources, and reach conclusions grounded in that understanding.

That’s not what Watson was. Watson required massive human curation to function in any new domain. Every new application required subject-matter experts to spend thousands of hours encoding the right questions, the right knowledge structures, the right evaluation criteria. For Jeopardy!, IBM had done that work internally, invisibly, over years of development. The “intelligence” that Watson displayed on national television was the product of an enormous amount of human intellectual labor that happened before the cameras turned on.

When Watson was deployed in oncology, the expectation — created by IBM’s marketing — was that the machine learning would understand the domain from PubMed papers and clinical notes. It couldn’t. The gap between what Watson needed to function and what clients were told it needed was the width of the entire project failure. The technology was real. The representation of what the technology could do independently was not.

This is the thing that should alarm anyone watching enterprise AI deployments in 2026: the gap between what was sold and what was delivered at IBM Watson was not primarily a technology gap. The gap was a gap between what the system required from humans to function and what was disclosed to clients about those requirements. The system was sold as autonomous. It was not autonomous. That misrepresentation, repeated across dozens of enterprise contracts, produced dozens of expensive failures.

Walk through any major enterprise AI deployment announced in the past three years and you will find the same structure.

A company deploys an LLM-based system for customer service. The demos are impressive. The benchmark numbers look good. The vendor’s case studies all involve carefully chosen clients with well-structured, predictable problems. Then the deployment happens in a real environment with real customer queries — edge cases, unusual phrasing, problems that fall between defined categories, users who are angry or confused or not describing their actual problem. Performance degrades sharply from the demo. The company hires people to review AI outputs and correct them. That team grows. Eventually the company is spending more on the human review team than it saved by deploying the AI. Nobody writes a press release about this.

Or a law firm deploys an AI research assistant. Partners are told it can draft preliminary research memos. What nobody explains clearly is that the system confidently produces citations to cases that don’t exist, interpolates legal reasoning that sounds correct and is subtly wrong, and performs much worse on novel fact patterns than on standard doctrine the model has seen many times. The associates who were supposed to be freed up now spend their time fact-checking the AI’s work, which takes as long as doing the research themselves but feels worse because they’re auditing rather than creating. Billable hours don’t decrease. Partner confidence in the tool evaporates after the third bad citation.

These aren’t hypothetical scenarios. They’re composite descriptions of documented failures across enterprise AI deployments since 2022. The specific details vary. The structure is identical to Watson.

IBM made one choice that sealed Watson’s fate, and it’s the same choice every major enterprise AI vendor is making today: they decided to compete on ambition rather than accuracy.

Honest product positioning would have looked like this: “We have a system that does X very well under Y conditions, requires Z hours of domain expert curation to deploy in a new domain, and will perform significantly worse on problems outside domain P. It’s genuinely valuable within those constraints, and here is our evidence for that value.” That’s a product you can sell, though the market is smaller and the contract values are lower.

Ambitious positioning looked like this: “Watson is a cognitive computing platform that will transform oncology. It reasons through problems, learns from clinical experience, and improves its recommendations over time.” That’s a story you can sell to CEOs and hospital boards and insurance company executives who don’t know enough to evaluate the technical claims. IBM’s stock responded to Watson announcements. Revenue projections were built on the ambitious framing. Contracts were signed based on it.

The gap between those two things — the honest description and the ambitious description — is exactly the gap between what the system could deliver and what clients expected. And that gap, multiplied across the entire Watson enterprise business, is what produced the billion-dollar write-off.

The current AI moment is running the same playbook. “Agents” that autonomously complete complex workflows without human oversight. “AI employees” that work independently. Systems that “understand” your business context and make decisions on your behalf. Every one of these framings overstates autonomy and understates the human infrastructure required to make the system actually function reliably. Watson should have made us permanently, constitutionally skeptical of that vocabulary. It hasn’t, because the economic incentives to oversell are enormous and the costs land on clients, not vendors, years after the initial contract is signed.

There is a longer structural point here that goes beyond IBM and beyond this particular hype cycle.

Enterprise AI deployments have a specific economic shape that makes them structurally prone to this failure pattern. They require massive upfront investment from clients — integration costs, organizational change management, training, vendor fees. The returns are uncertain and long-delayed. The clients who make these bets are not stupid — they’re responding to real competitive pressure. If your competitors are all deploying AI and getting even modest efficiency gains, you can’t afford to wait for the technology to mature to the point where the representations match the reality. You buy the hype because the alternative is falling behind.

This creates a market structure that systematically rewards overselling. Vendors who oversell get the contracts. Vendors who are honest about limitations lose to the oversellers in competitive bids. Over time, the honest vendors fold or get acquired by the oversellers. The clients are left with expensive commitments to systems that don’t do what was promised, and the vendors have already moved on to the next pitch.

IBM wasn’t uniquely dishonest. IBM was responding to market incentives that pointed strongly in the direction of maximum ambition. It got caught more visibly than most because the healthcare domain has external audits and the MD Anderson failure was documented. Most enterprise AI failures are quieter — the project gets quietly scaled back, the team that championed it gets reorganized away, the vendor blames “implementation challenges” and the client blames “change management failures,” and nobody ever publishes the $62 million audit.

There’s another dimension worth noting: the people inside IBM who understood Watson’s actual capabilities and limitations were not the people writing the press releases or negotiating the enterprise contracts. David Ferrucci’s engineering team knew exactly what Watson was and wasn’t. The sales organization knew what would win the deal. These two groups had different incentives and different information, and the organizational structure ensured that the sales narrative — not the engineering reality — was what reached clients. This is not a problem specific to IBM. It’s endemic to any organization where the team with product knowledge is structurally separated from the team making deployment claims.

The same organizational dynamic operates at every major AI company today. The ML engineers who understand where GPT-4 or Claude fails reliably are not the people producing the marketing materials or negotiating the enterprise contracts. Product marketing teams are optimizing for what wins deals. The information asymmetry between what the builders know and what the buyers are told is not an accident of communication — it’s a structural feature of how technology companies are organized and incentivized.

When the current generation of enterprise AI deployments starts visibly failing — and some will, in auditable, dollar-figure-attached ways — the postmortems will look familiar. Overpromised autonomy. Underestimated human curation requirements. Performance that held up in demo conditions and degraded in production. Client organizations that didn’t have the internal expertise to evaluate what they were buying. Vendors who were technically honest in the fine print and thoroughly misleading in the pitch.

Watson is not history. Watson is a preview. The only question is whether enough people will have learned from it before the next multi-billion-dollar auditors’ report lands.